AJNA BioSciences and Charlotte's Web to Spotlight Cannabis' Pharmaceutical Future at Benzinga Cannabis Capital Conference Featuring DeFloria
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2025
0mins
Source: PRnewswire
Industry Shift: DeFloria, Inc. is set to discuss the transition from recreational cannabis to pharmaceutical applications at the Benzinga Cannabis Capital Conference, highlighting a projected $1 trillion market shift towards FDA-approved therapeutic options for conditions like autism spectrum disorder (ASD).
Innovative Development: DeFloria's AJA001 oral solution, the first botanical drug to receive FDA clearance for Phase 2 trials, aims to address unmet clinical needs in ASD through a multi-compound formulation that enhances therapeutic efficacy while minimizing side effects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
